scholarly journals 11.9 Differences between ACE Inhibitor and Angiotensin II Receptor Blocker-based therapy in preventing myocardial infarction, stroke and cardiovascular mortality: a meta-analysis

2008 ◽  
Vol 15 (3) ◽  
pp. 305-305
Author(s):  
G. Reboldi ◽  
F. Angeli ◽  
C. Cavallini ◽  
G. Gentile ◽  
G. Mancia ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Angiotensin Ii ◽  
Cardiovascular Mortality ◽  
Ace Inhibitor ◽  
Meta Analysis ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor

Angiotensin II Receptor Blocker–Associated Angioedema: On the Heels of ACE Inhibitor Angioedema

2002 ◽  
Vol 22 (9) ◽  
pp. 1173-1175 ◽  
Author(s):  
Reza Abdi ◽  
Victor M. Dong ◽  
Cynthia J. Lee ◽  
K. Adu Ntoso
Keyword(s):  
Angiotensin Ii ◽  
Ace Inhibitor ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor

scholarly journals Diabetes mellitus is very common in drug resistant hypertension against angiotensin II receptor blocker and ACE inhibitor

2005 ◽  
Vol 18 (5) ◽  
pp. A57-A57
Author(s):  
K EGUCHI ◽  
K KARIO ◽  
J ISHIKAWA ◽  
S HOSHIDE ◽  
M MORINARI ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Angiotensin Ii ◽  
Resistant Hypertension ◽  
Ace Inhibitor ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Drug Resistant ◽  
Angiotensin Ii Receptor

scholarly journals Angiotensin II receptor blocker irbesartan attenuates cardiac dysfunction induced by myocardial infarction in the presence of renal failure

2015 ◽  
Vol 39 (4) ◽  
pp. 237-244 ◽  
Author(s):  
Ryo Watanabe ◽  
Jun-ichi Suzuki ◽  
Kouji Wakayama ◽  
Hidetoshi Kumagai ◽  
Yuichi Ikeda ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Renal Failure ◽  
Angiotensin Ii ◽  
Cardiac Dysfunction ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor

Combination ACE Inhibitors and Angiotensin II Receptor Blockers for Hypertension

2003 ◽  
Vol 37 (6) ◽  
pp. 886-889 ◽  
Author(s):  
Patrick M Finnegan ◽  
Brenda L Gleason
Keyword(s):  
Blood Pressure ◽  
Angiotensin Ii ◽  
Combination Therapy ◽  
Ace Inhibitors ◽  
Ace Inhibitor ◽  
Renin Angiotensin System ◽  
Reduce Blood Pressure ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor

OBJECTIVE: To review data concerning combined angiotensin-converting enzyme (ACE) inhibitor and angiotensin II receptor blocker (ARB) therapy for hypertension. DATA SOURCES: MEDLINE (1966–April 2003), IPA (1970–April 2003), and EMBASE (1974–April 2003) with search terms of ACE inhibitor, angiotensin receptor blocker, essential hypertension, and combination therapy. DATA SYNTHESIS: ACE inhibitors provide incomplete blockade of the renin–angiotensin system, sometimes leading to loss of blood pressure control. Addition of ARBs may in theory further reduce blood pressure. Studies of combined ACE inhibitor and ARB therapy for managing hypertension were evaluated. CONCLUSIONS: While studies have shown statistically significant blood pressure reductions with ACE/ARB combination therapy, clinical significance is lacking. Further trials are needed before routine use of the combination can be recommended.

scholarly journals The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based antihypertensive therapies—reply

2020 ◽  
Vol 15 (8) ◽  
pp. 1583-1584 ◽  
Author(s):  
Adriana Albini ◽  
Douglas McClain Noonan ◽  
Giuseppe Pelosi ◽  
Giovanni Di Guardo ◽  
Michele Lombardo
Keyword(s):  
Angiotensin Ii ◽  
Ace Inhibitor ◽  
Cell Types ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Different Cell Types
Sign in / Sign up

Export Citation Format

Share Document